CA3195872A1 - Promedicaments glp-1 et leurs utilisations - Google Patents

Promedicaments glp-1 et leurs utilisations

Info

Publication number
CA3195872A1
CA3195872A1 CA3195872A CA3195872A CA3195872A1 CA 3195872 A1 CA3195872 A1 CA 3195872A1 CA 3195872 A CA3195872 A CA 3195872A CA 3195872 A CA3195872 A CA 3195872A CA 3195872 A1 CA3195872 A1 CA 3195872A1
Authority
CA
Canada
Prior art keywords
chem
compound
compound according
glp
life
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3195872A
Other languages
English (en)
Inventor
Jesper F. Lau
Lennart LYKKE
Bhavesh PREMDJEE
Cecilie Mia Jorgensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from PCT/EP2021/080747 external-priority patent/WO2022096636A1/fr
Publication of CA3195872A1 publication Critical patent/CA3195872A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des promédicaments à base de dicétopipérazine (DKP). L'invention concerne également l'utilisation desdits promédicaments à base de DKP. Les promédicaments comprennent un polypeptide GLP-1, tel que le sémaglutide, et une fraction lipophile comprenant un acide carboxylique distal.
CA3195872A 2020-11-06 2021-11-05 Promedicaments glp-1 et leurs utilisations Pending CA3195872A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20206198.2 2020-11-06
EP20206198 2020-11-06
PCT/EP2021/080747 WO2022096636A1 (fr) 2020-11-06 2021-11-05 Promédicaments glp-1 et leurs utilisations

Publications (1)

Publication Number Publication Date
CA3195872A1 true CA3195872A1 (fr) 2022-05-12

Family

ID=73172549

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3195872A Pending CA3195872A1 (fr) 2020-11-06 2021-11-05 Promedicaments glp-1 et leurs utilisations

Country Status (2)

Country Link
AR (1) AR124010A1 (fr)
CA (1) CA3195872A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116159027A (zh) * 2022-12-29 2023-05-26 江苏诺泰澳赛诺生物制药股份有限公司 一种司美格鲁肽冻干药物组合物及其制备方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116159027A (zh) * 2022-12-29 2023-05-26 江苏诺泰澳赛诺生物制药股份有限公司 一种司美格鲁肽冻干药物组合物及其制备方法

Also Published As

Publication number Publication date
AR124010A1 (es) 2023-02-01

Similar Documents

Publication Publication Date Title
US10604555B2 (en) GIP derivatives and uses thereof
CN106117344B (zh) 双酰化glp-1衍生物
JP6352806B2 (ja) 新規のグルカゴン類似体
JP4585037B2 (ja) アシル化ｇｌｐ−１化合物
ES2672770T3 (es) Derivados del péptido-1 similar al glucagón y su uso farmacéutico
JP2007537141A (ja) 新規なｇｌｐ−１化合物
EP2560675A1 (fr) Dérivés de gastrine à action prolongée
JP7484018B2 (ja) Ｇｌｐ－１プロドラッグおよびその使用
KR20230029480A (ko) 경구 전달에 적합한 glp-1 및 gip 수용체에서의 공-작용제
BR112012029248B1 (pt) Análogo de glp-1 de fórmula i ou a sua composição, análogo de glp-1 de fórmula viii ou um sal farmaceuticamente aceitável ou a composição do mesmo, composição farmacêutica e uso de um composto
CA3195872A1 (fr) Promedicaments glp-1 et leurs utilisations
WO2023217744A1 (fr) Promédicaments de polypeptide glp-1 et leurs utilisations
CN116490212A (zh) Glp-1前药及其用途
JP7434616B2 (ja) プロドラッグおよびその使用